Journal History

2009 Inaugural issue was released, initially published as a quarterly journal.
2013 Indexed by PubMed (NLM) and Scopus.
2015 Changed to publish in article number order instead of in page range order.
2016 Changed to a monthly publication schedule. The Travel Awards project was launched to support young researchers in the field. The journal Twitter account was established.
2017 Covered by the Science Citation Index Expanded (SCIE).
2018 Cancers received a first Impact Factor of 5.326. The journal ranks 44/222 (Q1) in the 'Oncology' category.

Cancers received an Impact Factor of 6.162. The journal ranks 31/229 (Q1) in the 'Oncology' category in JCR.
Cancers published more than 2000 papers in the year of 2019.
Cancers became an affiliated journal of Signal Transduction Society (STS).


Cancers established the following topical sections:

Cancers announced the first edition Outstanding Reviewer Awards and second edition Young Investigator Awards.


Cancers starts to be published semi-monthly online since January 2021.
Cancers received an Impact Factor of 6.639. The journal ranks 51/242 (Q1) in the 'Oncology' category.
Cancers established the following two new topical sections:
Pediatric Oncology;
Infectious Agents and Cancer;


2009–2015 Founding Editor-in-Chief: Prof. Dr. Robert H. Weiss
2015–present Editor-in-Chief: Prof. Dr. Samuel C. Mok
2016–present Associate Editor: Prof. Dr. David Wong
2017–present Associate Editor: Dr. Deepak Nagrath
2020–present Associate Editor: Prof. Dr. Mary Frances McMullin

Section Editor-in-Chief

2020–present Section Editor-in-Chief: Dr. Carlos S. Moreno for section Cancer Biomarkers
Section Editor-in-Chief:
Prof. Dr. Donat Kögel for section Molecular Cancer Biology
Section Editor-in-Chief:
Dr. Barbara Wegiel for section Cancer Immunology and Immunotherapy
Section Editor-in-Chief:
Dr. Nicola Amodio for section Cancer Pathophysiology
Section Editor-in-Chief:
Prof. Dr. Sanjay Gupta for section Tumor Microenvironment
Section Editor-in-Chief:
Dr. Kevin Camphausen for section Cancer Therapy
Section Editor-in-Chief:
Prof. Dr. Alexandre Escargueil for section Cancer Therapy
Section Editor-in-Chief:
Prof. Dr. Massimo Di Maio for section Systematic Review or Meta-Analysis in Cancer Research
Section Editor-in-Chief:
Prof. Dr. Fiona Lyng for section Methods and Technologies Development
Section Editor-in-Chief:
Dr. Jason Roszik for section Cancer Informatics and Big Data
Section Editor-in-Chief:
Prof. Dr. Massoud Mirshahi for section Cancer Causes, Screening and Diagnosis
Associate Section Editor-in-Chief:
Dr. J. Chad Brenner for section Cancer Informatics and Big Data
Associate Section Editor-in-Chief:
Dr. Subree Subramanian for section Cancer Immunology and Immunotherapy
Associate Section Editor-in-Chief:
Prof. Dr. Dario Marchetti for section Tumor Microenvironment
Associate Section Editor-in-Chief:
Dr. Giovanna Tosato for section Tumor Microenvironment
2020–2022 Section Editor-in-Chief: Prof. Dr. Eduardo Nagore for section Cancer Epidemiology and Prevention
2021–present Section Editor-in-Chief: Prof. Dr. Antoine Italiano for section Clinical Trials of Cancer
Back to TopTop